C2 CryoBalloon™ Endoscopic Device Uses Extreme Cold to Eradicate Precancerous Lesions

Endoscopy company, Pentax Medical has announced the introduction of the C2 CryoBalloon™ Ablation System for the treatment of Barrett’s esophagus.

Background

Barrett’s esophagus is a condition in which the lining of the esophagus develops abnormal lesions primarily as a result of chronic gastroesophageal reflux disease (GERD). It is a known pre-cancerous condition, with sufferers being 30-40 times more likely to develop esophageal cancer, a disease with only a 19.2% five-year survival rate.

As its name implies, the C2 CryoBalloon Ablation System uses extreme cold to destroy unwanted tissue. A balloon probe, which is connected to a catheter, comes in contact with the wall of the target tissue. Upon activation by a physician, the balloon probe is simultaneously cooled and inflated with nitrous oxide. The extreme cold eradicates the targeted precancerous or abnormal lesions along the esophageal lining while sparing healthy tissue. The system allows physicians complete control of the procedure under direct visualization of the treatment area during the procedure, which lasts between 15 to 30 minutes.

According to clinical studies, 95 percent of patients treated with the C2 CryoBalloon achieve complete eradication of dysplasia (CED) and 90 percent have complete eradication of intestinal metaplasia (CEIM) through two years. Additionally, one week following treatment, no patients required narcotic pain medication.

Pentax Medical is featuring the device at Digestive Disease Week™ (DDW) in Washington, DC this week (June 2–5). DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

The company has also announced that beginning June 1, the developer of the C2 CryoBalloon, C2 Therapeutics, which it acquired last year, will operate under the PENTAX Medical name.

Company comments

“We are committed to advancing the treatment of Barrett’s esophagus with a new generation of ablation devices that are easy to use and improve clinical outcomes and patient satisfaction,” said David Woods, Global Chief Marketing Officer, PENTAX Medical. “The C2 CryoBalloon strengthens our therapeutic endoscopy portfolio and is an important technology that enables endoscopists to improve the quality of care they provide to their patients.”

Source: Pentax Medical

Share your thoughts

Your email address will not be published. Required fields are marked *